Association of Pharmacological Interventions With Symptom Burden Reduction in Patients With Mild Traumatic Brain Injury: A Systematic Review.

Abstract:

Importance:Mild traumatic brain injury (TBI) is experienced by 55.9 million people globally each year. The symptoms of mild TBI are diverse and sometimes long-lasting, requiring frequent use of pharmacological interventions to mitigate them. A thorough understanding of the data supporting pharmacological interventions is important for decision-making among clinicians treating this common injury. Objective:To systematically review studies of pharmacological interventions and their associations with symptom burden reduction among patients with mild TBI and to use an evidence-based model to identify potential directions for future research that may aid in clinical decision-making. Evidence Review:A systematic review was performed in PubMed, Scopus, and Web of Science. Search strings modified for the advanced search interfaces of each search engine were developed in consultation with a librarian and included combinations of search terms, such as brain concussion, post-concussion syndrome, mild traumatic brain injury, and pharmacological treatment. Articles published between January 1, 2000, and July 1, 2020, were analyzed. Studies were included if (1) they were clinical studies with discrete analyses of participants with mild TBI or complicated mild TBI, (2) they were assessments of a pharmacological intervention, (3) they included human participants, and (4) they were published in a peer-reviewed journal in the English language. Studies were excluded if the severity of TBI among participants could not be ascertained (ie, inadequate definition of mild TBI) and the inclusion criteria for the study required intracranial hemorrhage. A total of 23 studies examining 20 pharmacological interventions met the inclusion criteria. Risk of bias was assessed using the Cochrane Risk of Bias for Randomized Trials (for randomized clinical trials) and the Cochrane Risk of Bias in Non-Randomized Studies of Interventions (for all other studies). Data were analyzed from June to September 2020. Findings:A total of 1495 articles were identified; of those, 131 articles were excluded as duplicates. Titles and abstracts were screened for inclusion and exclusion criteria among the remaining 1364 articles, and 134 of those articles received a full-text review. After exclusions, 23 studies (11 randomized clinical trials, 7 prospective observational studies, 3 retrospective observational studies, and 2 case studies) examining 20 pharmacological interventions were identified for inclusion in the systematic review. Studies included 22 distinct participant populations comprising 8277 participants with mild TBI and 45 participants without TBI. Among 23 total studies, 8 studies specifically addressed the pediatric population, 9 studies had a low risk of bias, and 16 studies reported symptom burden reduction. Of the 20 pharmacological interventions examined in the studies, methylphenidate, sertraline hydrochloride, ondansetron, amitriptyline, and melatonin were the only medications included in multiple studies. Conclusions and Relevance:This systematic review found a limited number of high-quality, clinically meaningful studies, particularly among children and individuals in the acute stage of injury; therefore, performing an evidence-based analysis that would inform clinical decision-making was not possible. Future studies are needed to focus on standardizing measures and increasing sample sizes (including large multicenter clinical trials) to generate a body of research that may provide additional options for the treatment of patients with mild TBI.

journal_name

JAMA Neurol

journal_title

JAMA neurology

authors

Feinberg C,Carr C,Zemek R,Yeates KO,Master C,Schneider K,Bell MJ,Wisniewski S,Mannix R

doi

10.1001/jamaneurol.2020.5079

subject

Has Abstract

pub_date

2021-01-19 00:00:00

eissn

2168-6149

issn

2168-6157

pii

2774864

pub_type

杂志文章
  • Association of 3.0-T brain magnetic resonance imaging biomarkers with cognitive function in the Dallas Heart Study.

    abstract:IMPORTANCE:Understanding the relationships between age-related changes in brain structure and cognitive function has been limited by inconsistent methods for assessing brain imaging, small sample sizes, and racially/ethnically homogeneous cohorts with biased selection based on risk factors. These limitations have preve...

    journal_title:JAMA neurology

    pub_type: 杂志文章

    doi:10.1001/jamaneurol.2014.3418

    authors: Gupta M,King KS,Srinivasa R,Weiner MF,Hulsey K,Ayers CR,Whittemore A,McColl RW,Rossetti HC,Peshock RM

    更新日期:2015-02-01 00:00:00

  • SQSTM1 mutations in French patients with frontotemporal dementia or frontotemporal dementia with amyotrophic lateral sclerosis.

    abstract:IMPORTANCE:Mutations in the SQSTM1 gene, coding for p62, are a cause of Paget disease of bone and amyotrophic lateral sclerosis (ALS). Recently, SQSTM1 mutations were confirmed in ALS, and mutations were also identified in 3 patients with frontotemporal dementia (FTD), suggesting a role for SQSTM1 in FTD. OBJECTIVE:To...

    journal_title:JAMA neurology

    pub_type: 杂志文章

    doi:10.1001/jamaneurol.2013.3849

    authors: Le Ber I,Camuzat A,Guerreiro R,Bouya-Ahmed K,Bras J,Nicolas G,Gabelle A,Didic M,De Septenville A,Millecamps S,Lenglet T,Latouche M,Kabashi E,Campion D,Hannequin D,Hardy J,Brice A,French Clinical and Genetic Research Net

    更新日期:2013-11-01 00:00:00

  • Endovascular Treatment for Patients With Acute Stroke Who Have a Large Ischemic Core and Large Mismatch Imaging Profile.

    abstract:Importance:Endovascular therapy (ET) is typically not considered for patients with large baseline ischemic cores (irreversibly injured tissue). Computed tomographic perfusion (CTP) imaging may identify a subset of patients with large ischemic cores who remain at risk for significant infarct expansion and thus could sti...

    journal_title:JAMA neurology

    pub_type: 杂志文章

    doi:10.1001/jamaneurol.2016.3954

    authors: Rebello LC,Bouslama M,Haussen DC,Dehkharghani S,Grossberg JA,Belagaje S,Frankel MR,Nogueira RG

    更新日期:2017-01-01 00:00:00

  • Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease.

    abstract:IMPORTANCE:Synaptic loss is an early pathologic substrate of Alzheimer disease (AD). Neurogranin is a postsynaptic neuronal protein that has demonstrated utility as a cerebrospinal fluid (CSF) marker of synaptic loss in AD. OBJECTIVE:To investigate the diagnostic and prognostic utility of CSF neurogranin levels in a l...

    journal_title:JAMA neurology

    pub_type: 杂志文章

    doi:10.1001/jamaneurol.2016.0086

    authors: Tarawneh R,D'Angelo G,Crimmins D,Herries E,Griest T,Fagan AM,Zipfel GJ,Ladenson JH,Morris JC,Holtzman DM

    更新日期:2016-05-01 00:00:00

  • Retinal Architecture and Melanopsin-Mediated Pupillary Response Characteristics: A Putative Pathophysiologic Signature for the Retino-Hypothalamic Tract in Multiple Sclerosis.

    abstract:Importance:A neurophysiologic signature of the melanopsin-mediated persistent constriction phase of the pupillary light reflex may represent a surrogate biomarker for the integrity of the retinohypothalamic tract, with potential utility for investigating alterations in homeostatic mechanisms associated with brain disor...

    journal_title:JAMA neurology

    pub_type: 杂志文章

    doi:10.1001/jamaneurol.2016.5131

    authors: Meltzer E,Sguigna PV,Subei A,Beh S,Kildebeck E,Conger D,Conger A,Lucero M,Frohman BS,Frohman AN,Saidha S,Galetta S,Calabresi PA,Rennaker R,Frohman TC,Kardon RH,Balcer LJ,Frohman EM

    更新日期:2017-05-01 00:00:00

  • A 2-Step Cerebrospinal Algorithm for the Selection of Frontotemporal Lobar Degeneration Subtypes.

    abstract:Importance:Cerebrospinal fluid (CSF) core Alzheimer disease (AD) biomarkers have shown an excellent capacity for the in vivo detection of AD. Previous studies have shown that CSF levels of phosphorylated tau (p-tau) also correlate with tau pathology in frontotemporal lobar degeneration (FTLD) after accounting for AD co...

    journal_title:JAMA neurology

    pub_type: 杂志文章

    doi:10.1001/jamaneurol.2018.0118

    authors: Lleó A,Irwin DJ,Illán-Gala I,McMillan CT,Wolk DA,Lee EB,Van Deerlin VM,Shaw LM,Trojanowski JQ,Grossman M

    更新日期:2018-06-01 00:00:00

  • Insights from LGI1 and CASPR2 potassium channel complex autoantibody subtyping.

    abstract:OBJECTIVE:To determine, in patients identified as seropositive for neuronal voltage-gated potassium channel (VGKC) complex autoantibodies, the spectrum of clinical presentations and frequency of leucine-rich glioma-inactivated protein 1 (LGI1) and contactin-associated protein-like 2 (CASPR2) as defined antigenic neuron...

    journal_title:JAMA neurology

    pub_type: 杂志文章

    doi:10.1001/jamaneurol.2013.592

    authors: Klein CJ,Lennon VA,Aston PA,McKeon A,O'Toole O,Quek A,Pittock SJ

    更新日期:2013-02-01 00:00:00

  • Interpreting Biomarker Results in Individual Patients With Mild Cognitive Impairment in the Alzheimer's Biomarkers in Daily Practice (ABIDE) Project.

    abstract:Importance:Biomarkers do not determine conversion to Alzheimer disease (AD) perfectly, and criteria do not specify how to take patient characteristics into account. Consequently, biomarker use may be challenging for clinicians, especially in patients with mild cognitive impairment (MCI). Objective:To construct biomark...

    journal_title:JAMA neurology

    pub_type: 杂志文章

    doi:10.1001/jamaneurol.2017.2712

    authors: van Maurik IS,Zwan MD,Tijms BM,Bouwman FH,Teunissen CE,Scheltens P,Wattjes MP,Barkhof F,Berkhof J,van der Flier WM,Alzheimer’s Disease Neuroimaging Initiative.

    更新日期:2017-12-01 00:00:00

  • Short-term Psychological Outcomes of Disclosing Amyloid Imaging Results to Research Participants Who Do Not Have Cognitive Impairment.

    abstract:Importance:The goal of preclinical Alzheimer disease (AD) clinical trials is to move diagnosis and treatment to presymptomatic stages, which will require biomarker testing and disclosure. Objective:To assess the short-term psychological outcomes of disclosing amyloid positron emission tomography results to older adult...

    journal_title:JAMA neurology

    pub_type: 杂志文章

    doi:10.1001/jamaneurol.2020.2734

    authors: Grill JD,Raman R,Ernstrom K,Sultzer DL,Burns JM,Donohue MC,Johnson KA,Aisen PS,Sperling RA,Karlawish J,A4 Study Team.

    更新日期:2020-08-10 00:00:00

  • Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial.

    abstract:Importance:Although levodopa remains the most effective oral pharmacotherapy for Parkinson disease (PD), its use is often limited by wearing off effect and dyskinesias. Management of such complications continues to be a significant challenge. Objective:To investigate the efficacy and safety of safinamide (an oral amin...

    journal_title:JAMA neurology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1001/jamaneurol.2016.4467

    authors: Schapira AH,Fox SH,Hauser RA,Jankovic J,Jost WH,Kenney C,Kulisevsky J,Pahwa R,Poewe W,Anand R

    更新日期:2017-02-01 00:00:00

  • Prognostic Value of Spreading Depolarizations in Patients With Severe Traumatic Brain Injury.

    abstract:Importance:Advances in treatment of traumatic brain injury are hindered by the inability to monitor pathological mechanisms in individual patients for targeted neuroprotective treatment. Spreading depolarizations, a mechanism of lesion development in animal models, are a novel candidate for clinical monitoring in patie...

    journal_title:JAMA neurology

    pub_type: 杂志文章,多中心研究

    doi:10.1001/jamaneurol.2019.4476

    authors: Hartings JA,Andaluz N,Bullock MR,Hinzman JM,Mathern B,Pahl C,Puccio A,Shutter LA,Strong AJ,Vagal A,Wilson JA,Dreier JP,Ngwenya LB,Foreman B,Pahren L,Lingsma H,Okonkwo DO

    更新日期:2020-04-01 00:00:00

  • Skin α-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Parkinson Disease.

    abstract:Importance:Deposition of the pathological α-synuclein (αSynP) in the brain is the hallmark of synucleinopathies, including Parkinson disease (PD), Lewy body dementia (LBD), and multiple system atrophy (MSA). Whether real-time quaking-induced conversion (RT-QuIC) and protein misfolding cyclic amplification (PMCA) assays...

    journal_title:JAMA neurology

    pub_type: 杂志文章

    doi:10.1001/jamaneurol.2020.3311

    authors: Wang Z,Becker K,Donadio V,Siedlak S,Yuan J,Rezaee M,Incensi A,Kuzkina A,Orrú CD,Tatsuoka C,Liguori R,Gunzler SA,Caughey B,Jimenez-Capdeville ME,Zhu X,Doppler K,Cui L,Chen SG,Ma J,Zou WQ

    更新日期:2020-09-28 00:00:00

  • Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease.

    abstract:IMPORTANCE:Neurogranin (NGRN) seems to be a promising novel cerebrospinal fluid (CSF) biomarker for synaptic loss; however, clinical, and especially longitudinal, data are sparse. OBJECTIVE:To examine the utility of NGRN, with repeated CSF sampling, for diagnosis, prognosis, and monitoring of Alzheimer disease (AD). ...

    journal_title:JAMA neurology

    pub_type: 杂志文章

    doi:10.1001/jamaneurol.2015.1867

    authors: Kester MI,Teunissen CE,Crimmins DL,Herries EM,Ladenson JH,Scheltens P,van der Flier WM,Morris JC,Holtzman DM,Fagan AM

    更新日期:2015-11-01 00:00:00

  • Prevalence of Invalid Performance on Baseline Testing for Sport-Related Concussion by Age and Validity Indicator.

    abstract:Importance:Estimated base rates of invalid performance on baseline testing (base rates of failure) for the management of sport-related concussion range from 6.1% to 40.0%, depending on the validity indicator used. The instability of this key measure represents a challenge in the clinical interpretation of test results ...

    journal_title:JAMA neurology

    pub_type: 杂志文章

    doi:10.1001/jamaneurol.2018.0031

    authors: Abeare CA,Messa I,Zuccato BG,Merker B,Erdodi L

    更新日期:2018-06-01 00:00:00

  • Predictors of hematoma volume in deep and lobar supratentorial intracerebral hemorrhage.

    abstract:IMPORTANCE:Hematoma volume is the strongest predictor of outcome in intracerebral hemorrhage (ICH). Despite known differences in the underlying biology between deep and lobar ICHs, limited data are available on location specificity of factors reported to affect hematoma volume. OBJECTIVE:To evaluate whether determinan...

    journal_title:JAMA neurology

    pub_type: 杂志文章

    doi:10.1001/jamaneurol.2013.98

    authors: Falcone GJ,Biffi A,Brouwers HB,Anderson CD,Battey TW,Ayres AM,Vashkevich A,Schwab K,Rost NS,Goldstein JN,Viswanathan A,Greenberg SM,Rosand J

    更新日期:2013-08-01 00:00:00

  • Reactions to Multiple Ascending Doses of the Microtubule Stabilizer TPI-287 in Patients With Alzheimer Disease, Progressive Supranuclear Palsy, and Corticobasal Syndrome: A Randomized Clinical Trial.

    abstract:Importance:Basket-design clinical trials that allow investigation of treatment effects on different clinical syndromes that share the same molecular pathophysiology have not previously been attempted in neurodegenerative disease. Objective:To assess the safety, tolerability, and pharmacodynamics of the microtubule sta...

    journal_title:JAMA neurology

    pub_type: 杂志文章,随机对照试验

    doi:10.1001/jamaneurol.2019.3812

    authors: Tsai RM,Miller Z,Koestler M,Rojas JC,Ljubenkov PA,Rosen HJ,Rabinovici GD,Fagan AM,Cobigo Y,Brown JA,Jung JI,Hare E,Geldmacher DS,Natelson-Love M,McKinley EC,Luong PN,Chuu EL,Powers R,Mumford P,Wolf A,Wang P,Sham

    更新日期:2020-02-01 00:00:00

  • Multiple system atrophy and amyotrophic lateral sclerosis in a family with hexanucleotide repeat expansions in C9orf72.

    abstract:IMPORTANCE:Here we report a family with coexistence of multiple system atrophy (MSA) and amyotrophic lateral sclerosis (ALS) with hexanucleotide repeat expansions in C9orf72. OBSERVATIONS:A 65-year-old woman had a 2-year history of ataxia with autonomic dysfunction but without motor neuron signs. She was diagnosed as ...

    journal_title:JAMA neurology

    pub_type: 杂志文章

    doi:10.1001/jamaneurol.2013.5762

    authors: Goldman JS,Quinzii C,Dunning-Broadbent J,Waters C,Mitsumoto H,Brannagan TH 3rd,Cosentino S,Huey ED,Nagy P,Kuo SH

    更新日期:2014-06-01 00:00:00

  • Prevalence of Aging, Dementia, and Multimorbidity in Older Adults With Down Syndrome.

    abstract:Importance:As the life expectancy of people with Down syndrome (DS) has markedly increased over the past decades, older adults with DS may be experiencing a higher incidence of aging conditions. In addition to longevity, the amyloid precursor protein gene located on chromosome 21 places individuals with DS at a high ri...

    journal_title:JAMA neurology

    pub_type: 杂志文章

    doi:10.1001/jamaneurol.2018.2210

    authors: Bayen E,Possin KL,Chen Y,Cleret de Langavant L,Yaffe K

    更新日期:2018-11-01 00:00:00

  • Longitudinally extensive transverse myelitis with and without aquaporin 4 antibodies.

    abstract:IMPORTANCE:Aquaporin 4 antibody (AQP4-Ab)-negative patients with longitudinally extensive transverse myelitis (LETM) behave differently from those with AQP4-Ab. Aquaporin 4 antibody-negative neuromyelitis optica (NMO) is rare when good assays are used. OBJECTIVE:To assess if AQP4-Ab-negative patients with LETM share s...

    journal_title:JAMA neurology

    pub_type: 杂志文章

    doi:10.1001/jamaneurol.2013.3890

    authors: Kitley J,Leite MI,Küker W,Quaghebeur G,George J,Waters P,Woodhall M,Vincent A,Palace J

    更新日期:2013-11-01 00:00:00

  • Association of pituitary adenylate cyclase-activating polypeptide with cognitive decline in mild cognitive impairment due to Alzheimer disease.

    abstract:IMPORTANCE:There is a deficit of pituitary adenylate cyclase-activating polypeptide (PACAP) in patients with neuropathologically confirmed Alzheimer dementia. However, whether this deficit is associated with the earlier stages of Alzheimer disease (AD) is unknown. This study was conducted to clarify the association bet...

    journal_title:JAMA neurology

    pub_type: 杂志文章

    doi:10.1001/jamaneurol.2014.3625

    authors: Han P,Caselli RJ,Baxter L,Serrano G,Yin J,Beach TG,Reiman EM,Shi J

    更新日期:2015-03-01 00:00:00

  • Episodic bradycardia as neurocardiac prodrome to voltage-gated potassium channel complex/leucine-rich, glioma inactivated 1 antibody encephalitis.

    abstract:IMPORTANCE:Voltage-gated potassium channel complex antibody (VGKCc-Ab) encephalitis is an immunotherapy-responsive syndrome usually associated with causative antibodies that target the leucine-rich, glioma inactivated 1 (LGI1) protein. Although it is expressed throughout the brain, LGI1 is not known to be expressed in ...

    journal_title:JAMA neurology

    pub_type: 杂志文章

    doi:10.1001/jamaneurol.2014.1234

    authors: Naasan G,Irani SR,Bettcher BM,Geschwind MD,Gelfand JM

    更新日期:2014-10-01 00:00:00

  • Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression.

    abstract:IMPORTANCE:The extent to which large-caliber axonal degeneration contributes to Alzheimer disease (AD) progression is unknown. Cerebrospinal fluid (CSF) neurofilament light (NFL) concentration is a general marker of damage to large-caliber myelinated axons. OBJECTIVE:To test whether CSF NFL concentration is associated...

    journal_title:JAMA neurology

    pub_type: 杂志文章

    doi:10.1001/jamaneurol.2015.3037

    authors: Zetterberg H,Skillbäck T,Mattsson N,Trojanowski JQ,Portelius E,Shaw LM,Weiner MW,Blennow K,Alzheimer’s Disease Neuroimaging Initiative.

    更新日期:2016-01-01 00:00:00

  • Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody.

    abstract:Importance:Recognizing the characteristics of myelin oligodendrocyte glycoprotein autoantibody (MOG-IgG) myelitis is essential for early accurate diagnosis and treatment. Objective:To evaluate the clinical, radiologic, and prognostic features of MOG-IgG myelitis and compare with myelitis with aquaporin-4-IgG (AQP4-IgG...

    journal_title:JAMA neurology

    pub_type: 杂志文章

    doi:10.1001/jamaneurol.2018.4053

    authors: Dubey D,Pittock SJ,Krecke KN,Morris PP,Sechi E,Zalewski NL,Weinshenker BG,Shosha E,Lucchinetti CF,Fryer JP,Lopez-Chiriboga AS,Chen JC,Jitprapaikulsan J,McKeon A,Gadoth A,Keegan BM,Tillema JM,Naddaf E,Patterson MC,Me

    更新日期:2019-03-01 00:00:00

  • Secular Trends of Amyotrophic Lateral Sclerosis: The Piemonte and Valle d'Aosta Register.

    abstract:Importance:This study reports the long-term epidemiologic trends of amyotrophic lateral sclerosis (ALS) based on a prospective register. Objective:To examine the 20-year epidemiologic trends of ALS in the Piemonte and Valle d'Aosta regions of Italy. Design, Setting, and Participants:The Piemonte and Valle d'Aosta Reg...

    journal_title:JAMA neurology

    pub_type: 杂志文章

    doi:10.1001/jamaneurol.2017.1387

    authors: Chiò A,Mora G,Moglia C,Manera U,Canosa A,Cammarosano S,Ilardi A,Bertuzzo D,Bersano E,Cugnasco P,Grassano M,Pisano F,Mazzini L,Calvo A,Piemonte and Valle d’Aosta Register for ALS (PARALS).

    更新日期:2017-09-01 00:00:00

  • Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple Sclerosis.

    abstract:Importance:It is unclear whether relapses and disease-modifying therapies are associated with the rate of disability accumulation in patients with secondary progressive multiple sclerosis (SPMS). Objective:To examine the association of relapses with the rate of disability accumulation in patients with SPMS and to asse...

    journal_title:JAMA neurology

    pub_type: 杂志文章

    doi:10.1001/jamaneurol.2020.2453

    authors: Lizak N,Malpas CB,Sharmin S,Havrdova EK,Horakova D,Izquierdo G,Eichau S,Lugaresi A,Duquette P,Girard M,Prat A,Larochelle C,Trojano M,Grand'Maison F,Grammond P,Sola P,Ferraro D,Hupperts R,Bergamaschi R,Boz C,Van Pe

    更新日期:2020-07-27 00:00:00

  • SOD1 in cerebral spinal fluid as a pharmacodynamic marker for antisense oligonucleotide therapy.

    abstract:BACKGROUND:Therapies designed to decrease the level of SOD1 are currently in a clinical trial for patients with superoxide dismutase (SOD1)-linked familial amyotrophic lateral sclerosis (ALS). OBJECTIVE:To determine whether the SOD1 protein in cerebral spinal fluid (CSF) may be a pharmacodynamic marker for antisense o...

    journal_title:JAMA neurology

    pub_type: 杂志文章

    doi:10.1001/jamaneurol.2013.593

    authors: Winer L,Srinivasan D,Chun S,Lacomis D,Jaffa M,Fagan A,Holtzman DM,Wancewicz E,Bennett CF,Bowser R,Cudkowicz M,Miller TM

    更新日期:2013-02-01 00:00:00

  • Autoimmune aquaporin-4 myopathy in neuromyelitis optica spectrum.

    abstract:IMPORTANCE:Documentation of muscle pathology compatible with targeting of sarcolemmal aquaporin-4 (AQP4) by complement-activating IgG implies involvement of organs beyond the central nervous system in neuromyelitis optica spectrum disorders. OBSERVATIONS:We report on a 51-year-old woman who had relapsing optic neuriti...

    journal_title:JAMA neurology

    pub_type: 杂志文章

    doi:10.1001/jamaneurol.2014.775

    authors: Guo Y,Lennon VA,Popescu BF,Grouse CK,Topel J,Milone M,Lassmann H,Parisi JE,Pittock SJ,Stefoski D,Balabanov R,Lucchinetti CF

    更新日期:2014-08-01 00:00:00

  • Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder.

    abstract:IMPORTANCE:Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune inflammatory disorder of the central nervous system. Recently, various immunosuppressant medications were introduced as therapeutic options for preventing relapse of NMOSD. However, our understanding of the effectiveness of mycophenolate mofetil...

    journal_title:JAMA neurology

    pub_type: 杂志文章,多中心研究

    doi:10.1001/jamaneurol.2014.2057

    authors: Huh SY,Kim SH,Hyun JW,Joung AR,Park MS,Kim BJ,Kim HJ

    更新日期:2014-11-01 00:00:00

  • Indirect measures of arterial stiffness and cognitive performance in individuals without traditional vascular risk factors or disease.

    abstract:IMPORTANCE:Whether cognition is influenced by arterial stiffness in the absence of vascular disease remains uncertain. OBJECTIVE:To test the hypotheses that indirect measures of arterial stiffness are important predictors of cognitive performance and that this relationship varies depending on the presence of vascular ...

    journal_title:JAMA neurology

    pub_type: 杂志文章

    doi:10.1001/jamaneurol.2014.3873

    authors: Gutierrez J,Marshall RS,Lazar RM

    更新日期:2015-03-01 00:00:00

  • Progress in Intravenous Thrombolytic Therapy for Acute Stroke.

    abstract:IMPORTANCE:Intravenous recombinant tissue plasminogen activator (alteplase) was approved by the US Food and Drug Administration in 1996 for the treatment of acute ischemic stroke. Nearly 20 years later, it remains the only approved treatment, despite limitations in both efficacy and safety. With a growing capacity for ...

    journal_title:JAMA neurology

    pub_type: 杂志文章,评审

    doi:10.1001/jamaneurol.2015.0835

    authors: Marshall RS

    更新日期:2015-08-01 00:00:00